My scientist finds fatty liver treats the new target to click

My scientist finds fatty liver treats the new target to click
My scientist finds fatty liver treats the new target to click
It is reported ' Reporter Wang Dan) Peking University medical science a cardiovascular research institute and research group which diabetic centre Professor Wang NanPing and Professor Zhu Yi led, publish the treatise at " whether liver learn " in study top magazine by liver recently, propose clearly for the first time, it is known as insulin to induce the gene 1 (INSIG-1) that the supersession nuclear receptor PPAR�� can activate one kind Inner for quality network albumen,can adjust the latter through inhibiting controlling synthetic firm alcohol of key factor of fat of cell component 1 (SREBP-1) of conjugated protelns Activity,what has been reduced people at hepatocyte thus directly fat piling up and diabetes mouse the formings of fatty livers littles fat. This result has offered the new target for treatment of the non- alcohol fatty liver to click. Wang NanPing shows when being interviewed by reporter, fatty liver and chronic liver pathological change formed by the fact that the fat of hepatocyte is piled up, can be divided into alcohol fatty liver and non- alcohol fatty liver, it is one of the chronic liver diseases of highest morbidity of our country. Among them, non- alcohol fatty liver is that supersession syndrome mainly behaves in one of the liver, one of the dangerous factors that happens that also glycosuria. At present, main therapeutic method including anti-oxidant treatment, insulin of disease these increase and treat and lower the drug therapy of lipoprotein etc. quickly. But take, keep on a diet, lower the method of the weight, prove to fat patient effective only, other therapeutic method results are unsatisfactory. Wang NanPing points out, PPAR�� excited pharmaceutical, except having potential effect on treatment of the non- alcohol fatty liver, it verifies, it may have multiple function on each clinical manifestation of supersession syndrome to study already. For example, PPAR�� excited pharmaceutical can increase the high density lipoprotein in the blood, strengthens insulinogenic sensitiveness, inhibit inflammation from reacting, can pass and increase the fatty acid oxidation of slow skin in the skin of skeleton, improve the movement ability of the little mouse, thus get the result of reducing the fat etc.. Wang NanPing points out at the same time, because there are differences between animal's model and the human body, have the prudent optimistic attitude on that the clinical application prospect of this result of study is drafted at present, clinical validity and security that use its must prove through loud sample clinical trial that control strictly.


|